Study on Skin Toxicity Related to Molecular Targeted Drugs for Treating Tumor from Februarial Theory

Abstract

Abstract: Molecular targeted drugs have become an important drug in the treatment of many tumors. However, skin toxicity is the main toxic side effect that occurs when targeted drugs exert anti-tumor efficacy, which seriously affects the quality of life of tumor patients during treatment. Therefore, alleviating the adverse reactions is particularly important for improving the treatment tolerance and quality of life of patients. From the clinical manifestation and evolution of skin toxicity, it is consistent with the evolution of warm and heat disease. The comprehensive diagnosis and treatment system of Wei Qi Ying Blood syndrome differentiation in febrile disease was adopted to carry out the "transparent method" thinking throughout the whole process of diagnosis and treatment, and achieved good clinical efficacy, providing the whole TCM intervention treatment idea for the treatment of targeted drug skin toxicity and improving the quality of life of tumor patients.

Key words: molecular targeted drugs, skin toxicity, Wei Qi Ying Blood, translucent

CLC Number:

R273

HU Xin-zhou, JIANG Bo, WU Zhen-zhen, ZHU Guo-qing, ZHOU Yi-lang, TIAN Jie. Study on Skin Toxicity Related to Molecular Targeted Drugs for Treating Tumor from Februarial Theory[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(7): 57-59.

References

[1] 刘颖,谢言,王新天.分子靶向抗肿瘤药物的毒性研究[J].医学信息,2021,34(14): 48-50.
[2] AN D, CHU W G, DAI F.Analysis of 125 cases of adverse reactions of bevacizumab injection[J]. Chin J Hosp Pharm(中国医院药学杂志),2013,33(9):749-751.
[3] SINGH A P, SHIN Y G, SHAH D K.Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development[J]. Pharm R, 2015,32:3508-3525.
[4] CHULAROJANAMONTRI L, TUCHINDA P,LIKITWATTANANURAK C,et al.Cutaneous toxicities of epidermal growth factor recep-tor inhibitors: a prospective study in 60 Asian patients[J]. Asian Pac J Allergy Immunol,2019,58(7):47-55.
[5] GUTZMER R, WOLLENBERG A, UGUREL S, et al.Cutaneousside effects of new antitumor drugs; clinical features and manage-ment[J]. Deut –sches rzteblatt International,2012,109(8):133.
[6] WAGNER L I,LACOUTURE M E.Dermatologic toxicities as、sociated with EGFR inhibitors:the clinical psychologists perspective. Impact on health-related quality of life and im、plications for clinical management of psychological sequelae[J]. Oncology,2007,21(5):34-36.
[7] LLOVET J M, MONTAL R,SIA D,et al.Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol,2018,15(10):599-616.
[8] PINTO C, BARONE CA, GIROLOMONI G,et al.Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy[J]. The Oncologist,2011,16(2):228-238.
[9] MACDONALD J B, M ACDONALD B,GOLITZ L E,et al. Cutane-ous adverse effects of targeted therapies[J]. J Am Acad Dermatol,2015,72(2):203-218.
[10] REVES-HABITO C M, ROH E K. Cutaneous reactions to che-motherapeutic drugs and targeted therapies for cancer[J]. Journalof the American Academy of Dermatology,2014,71(2):203-215.
[11] 张心悦. 表皮生长因子受体拮抗剂相关皮肤不良反应的变化规律及中医证型变化的临床研究[D].北京:北京中医药大学,2014.
[12] 蒋梅,纪丽芝.从温病学斑疹论治探析肿瘤分子靶向药物相关皮肤毒性的中医药应对策略[J].中医肿瘤学杂志,2019,1(5):18-22.
[13] 张小瑞,赵远红.非小细胞肺癌靶向药物相关皮肤毒性反应的中医辨治[J].中医杂志,2015,56(12):1065-1066.
[14] 戚益铭,徐国暑.从温病“透法”探讨表皮生长因子受体酪氨酸激酶抑制剂皮肤毒性的辨治思路[J].浙江中医杂志,2018,53(8):578-579.
[15] 侯天将,由凤鸣,祝捷,等.从“清、透、滋”三治则论治靶向药物皮肤毒性[J].四川中医,2017,35(10):28-30.
[16] 吴若云. 从温病卫气营血理论探讨急性皮肤病的病机与治法[J].光明中医,2020,35(14):2138-2140.
[17] 肖战说,崔炳南.《湿病条辨》斑疹理论初探[J].安徽中医药大学学报,2018,37(6):8-10.
[18] 吴若云. 从温病卫气营血理论探讨急性皮肤病的病机与治法[J].光明中医,2020,35(14):2138-2140.
[19] 余国芳. EGFRIs 相关皮肤毒性中医病因病机及辨证治疗分析[D].广州:广州中医药大学,2009.
[20] 余国芳,林丽珠.林丽珠辨治表皮生长因子受体抑制剂相关皮渗的经验探析[J].世界科学技术(中医药现代化),2009,11(5):758-763.